Phase I/Ib Trial of the MUC1 Inhibitor GO-203-2C Alone and in Combination with Decitabine for Acute Myeloid Leukemia
Jessica Liegel(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Josie Bazemore(Dana-Farber Cancer Institute), Victoria E. Allen(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Lillian Werner(Dana-Farber Cancer Institute), Leandra Cole(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Myrna Nahas, Mary Paty Bryant(Beth Israel Deaconess Medical Center), Kaleb Mikami(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Emma Logan(Beth Israel Deaconess Medical Center), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Adam Ephraim(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Abigail Washington(Beth Israel Deaconess Medical Center), Richard M. Stone(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 4
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k